NEN

NEN
Name	NEN
Specialty	Oncology; Endocrinology

NEN

NEN are a heterogeneous group of neoplasms arising from neuroendocrine cells found throughout the body. They variably secrete hormones and peptides, producing clinical syndromes that intersect with presentations seen in patients evaluated by specialists from oncology, endocrinology, gastroenterology, and pulmonology. Management pathways draw on models established in multidisciplinary centers associated with major institutions and guideline-producing bodies.

Definition and Nomenclature

Terminology for NEN has evolved across classifications developed by organizations such as the World Health Organization, the American Joint Committee on Cancer, and the European Neuroendocrine Tumor Society. Historic labels used by authors at institutions like Mayo Clinic, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center include carcinoid tumor, argentaffin tumor, and pancreatic neuroendocrine tumor, but modern lexicons emphasize grading and site-specific descriptors adopted in consensus statements from groups including the Union for International Cancer Control and national registries like the Surveillance, Epidemiology, and End Results Program. Nomenclature distinguishes by primary site (for example, pancreas, lung, or small intestine) and by proliferation indices endorsed by panels convened at meetings such as the American Association for Cancer Research annual conference.

Classification and Types

Classification systems use morphology, proliferative rate, and differentiation status. The WHO schemes applied in centers like Royal Free Hospital and research networks like the European Association for the Study of the Liver categorize well-differentiated neuroendocrine tumors versus poorly differentiated neuroendocrine carcinomas. Clinico-pathologic entities include pancreatic neuroendocrine tumors described by groups linked to Karolinska Institutet and bronchopulmonary carcinoids studied at institutions like Johns Hopkins Hospital. Subtypes often referenced in literature from universities such as Oxford University and Harvard Medical School include insulinoma, gastrinoma, VIPoma, and small-cell neuroendocrine carcinoma, each with characteristic secretory profiles and molecular footprints reported in consortia including the Cancer Genome Atlas.

Pathophysiology and Etiology

Pathophysiology integrates cellular neuroendocrine differentiation, receptor expression, and signaling pathways elucidated in studies from laboratories at Stanford University and Cold Spring Harbor Laboratory. Genetic predisposition is exemplified by hereditary syndromes investigated by clinics at National Institutes of Health and described in literature on multiple endocrine neoplasia type 1, von Hippel–Lindau disease, and neurofibromatosis type 1, where germline mutations drive tumorigenesis. Sporadic mutations, copy-number alterations, and epigenetic changes have been characterized in datasets curated by the European Genome-phenome Archive and research groups at Dana-Farber Cancer Institute, implicating pathways such as mTOR and angiogenesis targeted in trials led by cooperative groups like European Organisation for Research and Treatment of Cancer.

Clinical Presentation and Diagnosis

Clinical manifestations range from hormone-mediated syndromes documented in case series from Bellevue Hospital and Guy's Hospital to mass effect symptoms reported in surgical cohorts at Cleveland Clinic. Diagnostic strategies rely on biochemical assays validated in reference laboratories affiliated with Mayo Clinic and imaging modalities including somatostatin receptor scintigraphy and PET tracers developed in collaborations between University of California, Los Angeles and national radiology societies. Histopathological confirmation through immunohistochemistry using markers studied at Memorial Sloan Kettering Cancer Center and grading based on Ki-67 indices recommended by panels at WHO are central to staging frameworks implemented in cancer centers such as The Royal Marsden Hospital.

Management and Treatment

Therapeutic approaches follow protocols refined in randomized trials coordinated by cooperative groups like National Cancer Institute-sponsored networks and European Neuroendocrine Tumor Society. Options include surgical resection practiced at high-volume centers such as University College Hospital, locoregional therapies employed by interventional teams at Mayo Clinic, systemic therapies including somatostatin analogues introduced in trials at Karolinska Institutet, targeted agents targeting mTOR and VEGF pathways investigated at GlaxoSmithKline and academic centers, and peptide receptor radionuclide therapy developed through collaborations involving Erasmus University Medical Center. Supportive care pathways mirror guidelines from societies such as the American Society of Clinical Oncology and palliative programs at institutions like St Christopher's Hospice.

Epidemiology and Prognosis

Epidemiologic patterns have been defined using registry data from Surveillance, Epidemiology, and End Results Program and national cancer registries in Denmark and Sweden, showing rising incidence attributed partly to improved detection in centers associated with tertiary hospitals. Prognosis varies by site, grade, and stage, with survival metrics reported in cohort studies from Johns Hopkins Hospital, Royal Infirmary of Edinburgh, and international pooled analyses coordinated through the International Agency for Research on Cancer. Predictive factors and outcome models have been incorporated into staging manuals published by the AJCC and guideline statements from the European Society for Medical Oncology.

Research and Controversies

Active research areas include biomarkers and liquid biopsy initiatives led by groups at Massachusetts General Hospital and Imperial College London, comparative effectiveness trials run by networks like National Institute for Health Research, and molecular taxonomy projects in collaboration with Broad Institute. Controversies engage stakeholders including academic centers and regulatory agencies over optimal sequencing of therapies, criteria for aggressive surgery debated in forums at Society of Surgical Oncology, and reimbursement for novel radionuclide therapies deliberated in health policy venues such as National Institute for Health and Care Excellence.

Category:Neoplasms